Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2017 Sep 22

PMID 28934427

Citations 18

Authors

Ifigeneia Tzannou

Sarah K Nicholas

Premal Lulla

Paibel I Aguayo-Hiraldo

Anisha Misra

Caridad A Martinez

Annette A Machado

Jordan S Orange

Pedro A Piedra

Juan F Vera

Ann M Leen

Affiliations

Soon will be listed here.

Abstract

Human metapneumovirus (hMPV) is a respiratory virus detected in ≥9% of allogeneic hematopoietic stem cell transplant (HSCT) recipients, in whom it can cause significant morbidity and mortality. Given the lack of effective antivirals, we investigated the potential for immunotherapeutic intervention, using adoptively transferred T cells. Thus, we characterized the cellular immune response to the virus and identified F, N, M2-1, M, and P as immunodominant target antigens. Reactive T cells were polyclonal (ie, they expressed CD4 and CD8), T-helper type 1 polarized, and polyfunctional (ie, they produced interferon γ, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and granzyme B), and they were able to kill autologous antigen-loaded targets. The detection of hMPV-specific T cells in HSCT recipients who endogenously controlled active infections support the clinical importance of T-cell immunity in mediating protective antiviral effects. Our results demonstrate the feasibility of developing an immunotherapy for immunocompromised patients with uncontrolled infections.

Citing Articles

Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.

Koukoulias K, Papayanni P, Leen A, Vasileiou S Transfus Med Hemother. 2025; 52(1):5-26.

PMID: 39944414 PMC: 11813280. DOI: 10.1159/000540961.

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.

Papadopoulou A, Karavalakis G, Papadopoulou E, Xochelli A, Bousiou Z, Vogiatzoglou A Nat Med. 2023; 29(8):2019-2029.

PMID: 37460756 DOI: 10.1038/s41591-023-02480-8.

Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond.

Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, Yannaki E Hemasphere. 2023; 7(1):e809.

PMID: 36698615 PMC: 9831191. DOI: 10.1097/HS9.0000000000000809.

Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19.

Ogura H, Gohda J, Lu X, Yamamoto M, Takesue Y, Son A Nat Commun. 2022; 13(1):7063.

PMID: 36526616 PMC: 9758236. DOI: 10.1038/s41467-022-34655-1.

The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid.

Santak M, Matic Z Viruses. 2022; 14(3).

PMID: 35336928 PMC: 8955406. DOI: 10.3390/v14030521.

References

Carneiro B, Yokosawa J, Arbiza J, Costa L, Mirazo S, Nepomuceno L . Detection of all four human metapneumovirus subtypes in nasopharyngeal specimens from children with respiratory disease in Uberlândia, Brazil. J Med Virol. 2009; 81(10):1814-8. DOI: 10.1002/jmv.21555. View

Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Kobayashi K . Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J Med Virol. 2003; 72(2):304-6. DOI: 10.1002/jmv.10572. View

Peggs K, Verfuerth S, Pizzey A, Chow S, Thomson K, Mackinnon S . Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis. 2009; 49(12):1851-60. DOI: 10.1086/648422. View

Edwards K, Zhu Y, Griffin M, Weinberg G, Hall C, Szilagyi P . Burden of human metapneumovirus infection in young children. N Engl J Med. 2013; 368(7):633-43. PMC: 3662802. DOI: 10.1056/NEJMoa1204630. View

van den Hoogen B, van Doornum G, Fockens J, Cornelissen J, Beyer W, de Groot R . Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis. 2003; 188(10):1571-7. DOI: 10.1086/379200. View

Feuillet F, Lina B, Rosa-Calatrava M, Boivin G . Ten years of human metapneumovirus research. J Clin Virol. 2011; 53(2):97-105. DOI: 10.1016/j.jcv.2011.10.002. View

Renaud C, Xie H, Seo S, Kuypers J, Cent A, Corey L . Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013; 19(8):1220-6. PMC: 3752411. DOI: 10.1016/j.bbmt.2013.05.005. View

Doubrovina E, Oflaz-Sozmen B, Prockop S, Kernan N, Abramson S, Teruya-Feldstein J . Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2011; 119(11):2644-56. PMC: 3311278. DOI: 10.1182/blood-2011-08-371971. View

Souza J, Watanabe A, Carraro E, Granato C, Bellei N . Severe metapneumovirus infections among immunocompetent and immunocompromised patients admitted to hospital with respiratory infection. J Med Virol. 2012; 85(3):530-6. DOI: 10.1002/jmv.23477. View

10.

Leen A, Christin A, Myers G, Liu H, Cruz C, Hanley P . Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009; 114(19):4283-92. PMC: 2774556. DOI: 10.1182/blood-2009-07-232454. View

11.

Debur M, Vidal L, Stroparo E, Nogueira M, Almeida S, Takahashi G . Human metapneumovirus infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2009; 12(2):173-9. DOI: 10.1111/j.1399-3062.2009.00465.x. View

12.

Egli A, Bucher C, Dumoulin A, Stern M, Buser A, Bubendorf L . Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation. Infection. 2012; 40(6):677-84. PMC: 7099999. DOI: 10.1007/s15010-012-0279-9. View

13.

Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W . Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood. 2015; 125(12):1986-94. DOI: 10.1182/blood-2014-06-573725. View

14.

Hastings A, Gilchuk P, Joyce S, Williams J . Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells. Vaccine. 2016; 34(24):2663-70. PMC: 4875773. DOI: 10.1016/j.vaccine.2016.04.034. View

15.

Feuchtinger T, Opherk K, Bethge W, Topp M, Schuster F, Weissinger E . Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010; 116(20):4360-7. DOI: 10.1182/blood-2010-01-262089. View

16.

Papadopoulou A, Gerdemann U, Katari U, Tzannou I, Liu H, Martinez C . Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014; 6(242):242ra83. PMC: 4181611. DOI: 10.1126/scitranslmed.3008825. View

17.

Englund J, Boeckh M, Kuypers J, Nichols W, Hackman R, Morrow R . Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006; 144(5):344-9. DOI: 10.7326/0003-4819-144-5-200603070-00010. View

18.

van den Hoogen B, Bestebroer T, Osterhaus A, Fouchier R . Analysis of the genomic sequence of a human metapneumovirus. Virology. 2002; 295(1):119-32. DOI: 10.1006/viro.2001.1355. View

19.

Hoellein A, Hecker J, Hoffmann D, Gottle F, Protzer U, Peschel C . Serious outbreak of human metapneumovirus in patients with hematologic malignancies. Leuk Lymphoma. 2015; 57(3):623-7. DOI: 10.3109/10428194.2015.1067699. View

20.

Esper F, Boucher D, Weibel C, Martinello R, Kahn J . Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics. 2003; 111(6 Pt 1):1407-10. DOI: 10.1542/peds.111.6.1407. View